glp-1 drugs side effects Peptide/GLP-1 Complications: 11 Hidden Risks and You Must Know Managing Side Effects of GLP-1

Can Ozempic Help You Quit Smoking

1).29,32 With respect to the vascular system, rGLP-1 activation induces modest decreases in blood pressure,33,34 it has a vasodilator effect, improves arterial stiffness, and prevents atherosclerotic plaque formation-and has plaque stabilizing effects-through its anti-inflammatory and antiapoptotic effects as demonstrated in animal models.29,32,3538 Despite controversies about rGLP-1 expression in vascular smooth muscle and endothelial cells, studies have shown that arGLP-1 has antiproliferative effects on these cells,39 reduces oxidative stress, improves endothelial function, and increases nitric oxide production in experimental models.3540 In the heart they produce a discrete increase in heart rate (24 beats/min), although this does not seem to be associated with an increase in arrhythmias or cardiovascular events

Tissue distribution and biological functions beyond glucose metabolism: 2.2.1

Obesity Landscape - Final Thoughts Dosing The GLP-1 RA obesity market, driven by injectables, has seen historic levels of success, and near-term entrants are likely to provide more dosing options within the GLP-1 or GLP-1/GIP class Weight Loss Novel drugs in development are likely to be approved within the next 5 years, with improved weight loss efficacy compared to what Wegovy and Zepbound have demonstrated Body Comp The coming years will likely see increased data on muscle preservation and the quality of weight loss with novel MoAs, even if used in combination with GLP-1/incretin-targeting agents As the obesity market matures, how will patients think about the tradeoffs between efficacy, safety, and dosing/convenience with the availability of new drugs and more data

Notably, Huang et al

Canadian Access Pathways: Provincial Coverage, Timelines, and Costs Access to GLP-1 medications in Canada depends heavily on provincial health insurance, private coverage, and individual clinical criteria